Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK moves to support neurological care standards:

This article was originally published in Clinica

Executive Summary

The UK's national service framework (NSF) for long-term conditions, which sets out the standards announced in February 2001 for the diagnosis and treatment of neurological conditions, has moved a step closer to implementation. Last week, the Department of Health appointed the chair and deputy chair of its external reference group (ERG). These are Diana Whitworth, chief executive of Carers UK, and Professor Lynne Turner-Stokes, of King's College Hospital, London. They will be supported by Andy McKeon, director of Policy and Planning at the Department of Health. The ERG's remit, announced in June 2002, includes providing advice on how best to implement standards and to ensure adequate provision of equipment in the community. The group's membership will be announced soon.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT068548

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel